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We sought to study new-onset microalbuminuria, its
progression, and the decline of renal function in patients
with type 1 diabetes. Using a cohort of 109 patients who
developed new-onset microalbuminuria in the first 4 years
following enrollment in the 1st Joslin Kidney Study, we
simultaneously tracked the change in their renal function and
urinary albumin excretion. Of these, 79 patients were
followed for an average of 12 years after microalbuminuria
onset, wherein their glomerular filtration rate was estimated
by the Modification of Diet in Renal Disease Study formula
and compared with their microalbuminuria and proteinuria.
The concordance between these outcomes was weak.
Only 12 of the 23 patients who progressed to advanced
(stage 3–5) chronic kidney disease developed proteinuria,
which, in general, did not precede but accompanied the
progression to advanced chronic kidney disease. The
remaining 11 patients who developed advanced disease
had persistent microalbuminuria or returned to normal
albuminuria. Thus, we found that one-third of patients
with type 1 diabetes developed advanced chronic kidney
disease relatively soon after the onset of microalbuminuria
and this was not conditional on the presence of proteinuria.
Contrary to the existing concept of early nephropathy in
type 1 diabetes, less emphasis should be placed on the
mechanisms of progression to proteinuria and more placed
on mechanisms initiating and promoting the early decline
of renal function that eventually progresses to advanced
chronic kidney disease.
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Microalbuminuria has become firmly entrenched as the
primary predictive marker of risk for the eventual end-stage
renal disease. The genesis of this present model can be traced
to three small studies published in the 1980s.1–3 In total, 30
patients with prevalent microalbuminuria, defined by urinary
albumin excretion approximately in the range of 30–300mg/
min, were followed for 7 to 14 years, and advanced
nephropathy developed in 60–90% of them. In these studies,
the outcome was defined by the worsening of urinary
albumin excretion to proteinuria (frequently referred to as
‘macroalbuminuria’), but not by the development of
advanced chronic kidney disease (advanced CKD). The
findings of extraordinary high risk of progression to
proteinuria together with reports in cross-sectional clinical
studies of association between renal function impairment
and proteinuria gave plausibility to a simple model of
diabetic nephropathy comprising three sequential stages:
Microalbuminuria heralds proteinuria, which after long-term
exposure initiates the process of renal function loss that leads
to end stage-renal disease.4 This model has become the
paradigm for research on diabetic nephropathy and for the
development of its preventive and therapeutic protocols.5,6
Accordingly, therapy in patients with microalbuminuria
focused on prevention of proteinuria as the means to prevent
renal function decline. However, the evidence base for this
use of proteinuria as a surrogate biomarker for declining
renal function was not available because this had to await a
means to evaluate changes in renal function as well as
the natural history of abnormalities in urinary albumin
excretion. Half of the story, the natural history of albumin
excretion in the microalbuminuria range, was clarified
recently.7 Contrary to the three early studies, in a large
prospective systematic study microalbuminuria proved to be
a dynamic process that was more likely to remit to normal
albumin excretion than to progress to proteinuria. The 6-year
cumulative incidence of remission was approximately 50%,
whereas the risk of progression to proteinuria was only 15%.7
Similar findings were reported by others.8–11
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However, the other half of the story – the impact of these
changes in microalbuminuria on the risk of renal function
loss – was studied only partially. In the subsequent 8-year
follow-up study using slopes of renal function change over
time estimated on the basis of serum cystatin C concentra-
tions, we demonstrated that patients with microalbuminuria
had frequent early progressive renal function decline.12 That
study, however, combined prevalent cases with new-onset
cases of microalbuminuria and because of short follow-up
was not able to study the relationship between progression to
proteinuria and declining renal function to advanced CKD,
an outcome considered more clinically meaningful than the
slope of change in glomerular filtration rate (GFR) over time.
To explore this relationship, the simultaneous tracking of
renal function change and urinary albumin excretion in a
cohort of patients with new-onset microalbuminuria is
required. Absence of the knowledge of precise timing of
microalbuminuria onset would compromise the assessment
of subsequent renal function because a collection of prevalent
cases detected by a single screening examination would not
only lack early GFR measures, but would be biased by the
under-representation of patients who had rapid progression
from microalbuminuria to proteinuria or to advanced CKD.
Guided by these considerations, we examined further the
cohort of patients with new-onset microalbuminuria,13
which was included in the previous publication,12 by
extending follow-up to 12 years and using the measurements
of serum creatinine that were many times more frequently
carried out than measurements of serum cystatin C. In this
report we characterized the courses of urinary albumin
excretion changes and the development of advanced CKD
during 12 years of follow up.
RESULTS
Characteristics of the study subjects according to the
development of advanced CKD
The 79 subjects with new-onset microalbuminuria and
normal renal function were followed for a mean of 12.4±1.4
years, during which they had 15±8 GFRMDRD determina-
tions. Advanced CKD, defined by GFRMDRDo60ml/min per
1.73m2 (stage 3 or 4 CKD) or end-stage renal disease
requiring dialysis or transplant (stage 5 CKD), developed in
23 (29%) of the 79 subjects. Six of these cases developed end
stage renal disease over a mean of 10.6 years (range 8.8–11.8
years) from the time of microalbuminuria onset. The
remaining 17 cases developed stage 3 or 4 CKD, correspond-
ing to a GFRMDRD o60ml/min per 1.73m2, and had a total
follow-up time of 12.2±1.4 years. In none of the cases was
CKD owing to non-diabetic causes recognized. The remain-
ing 56 controls (71%) maintained a GFRMDRD of 60ml/min
per 1.73m2 or greater over 12.5±1.4 years of follow up.
The baseline characteristics of the 79 study subjects at the
time of microalbuminuria onset are summarized in Table 1
according to case–control status at the end of observation.
Table 1 | Baselinea characteristics of the 79 subjects according to case–control status at the end of follow-up
Controls (N=56) Cases (N=23)
Characteristic
GFR 460ml/min per 1.73m2
‘stages 1–2 CKD’
GFRp60ml/min per 1.73m2
‘stages 3–4 CKD’ (N=17)
ESRD ‘stage
5 CKD’ (N=6) Pb
Age at diabetes diagnosis (years) 13±7 14±10 15±10 0.38
Women (%) 33 (59%) 14 (82%) 5 (82%) 0.05
Age at baseline (years) 30±8 36±7 30±10 0.02
Diabetes duration (years)c 17±9 22±8 15±4 0.57
Current/past smoking (%) 60 65 40 0.61
Systolic BP (mmHg) 122±16 122±17 128±16 0.75
Diastolic BP (mmHg) 76±8 76±8 79±9 0.74
HbA1c (%) 9.0±1.4 9.5±1.8 11.5±1.1 0.01b
Total cholesterol (mg/dl)d 203±38 210±43 232±35 0.41
Albumin excretion (mg/min)
Median 49 40 46 0.33
Interquartile range 34–68 34–45 33–69
Serum creatinine (mg/dl) 0.86± 0.19 0.84±0.24 0.86±0.20 0.77
Serum cystatin C (mg/l) 0.70± 0.16 0.67±0.18 0.69±0.17 0.45
GFRMDRD (ml/min per 1.73m
2)e 107±26 98±23 101±25 0.77
GFRCYSTATIN C (ml/min per 1.73m
2)e 123±26 126±18 122±41 0.78
CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin A1c.
Except for albumin excretion rate, data are mean±s.d. or %.
aThe baseline period refers to the 2-year evaluation interval during which the onset of microalbuminuria occurred.
bComparison of cases and controls. Categorical variables report P-values for w2 test statistics and continuous variables report P-values for t-test for the two-way comparison
between cases and controls. P-values with an adjacent ‘b’ indicate variables with a statistically significant difference between those with stages 3–4 CKD and stage 5 CKD.
cDiabetes duration is calculated from date of onset without consideration to puberty.
dTo convert to mmoles/l, multiply by 0.02586.
eGFRMDRD represents the ‘four-variable’ equation from the Modification of Diet in Renal Disease Study.
12 GFRCYSTATIN C is calculated by the formula of MacIsaac, where
GFRCYSTATIN C in ml/min per 1.73m
2 = (86.7/cystatin C concentration) – 4.2.44
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A significantly older age at baseline and excess of women was
observed among cases. No differences in age at diabetes
diagnosis, diabetes duration, smoking, or blood pressure
were seen among controls and cases. Of the biochemical
variables, glycosylated hemoglobin A1c was significantly
higher in cases. However, neither cholesterol, the degree of
urinary albumin excretion, nor the level GFRMDRD or
GFRCYSTATIN C reflected future case status.
Magnitude of renal function decline
Despite a mean GFRMDRD for the 79 participants of
104±25ml/min per 1.73m2 at baseline evaluation, by the
last examination window, the mean value was 73±23ml/min
per 1.73m2. Table 2 illustrates the magnitude of renal
function change according to cases and controls. Although
controls maintained levels of GFRMDRDX60ml/min per
1.73m2, their mean value decreased from 107 to 84ml/min
per 1.73m2 over 12.5 years, representing a mean decline in
renal function of approximately 20% far exceeding expected
age-related decline.14 By definition, cases had a much greater
magnitude of decline in GFRMDRD, of approximately 50–75%
over 12 years.
Relationship between the development of advanced CKD and
progression to proteinuria
The mean urinary albumin excretion rate at baseline and in
the final interval of follow up is shown in the second section
of Table 2 for controls and cases. The only marked an
increase in albumin excretion rate occurred in the subset of
cases that developed end-stage renal disease (ESRD).
Subjects in the study were also classified into three
categories according to changes in albumin excretion rate
during the 12 years of follow up: those in whom
microalbuminuria regressed to normo-albuminuria, those
with persistent microalbuminuria, and those in whom
microalbuminuria progressed to proteinuria. Distribution
of controls and cases according to these categories is shown
in Table 2. Half of the controls had microalbuminuria, which
regressed to normo-albuminuria, 34% of them had persistent
microalbuminuria, and 16% of them developed proteinuria.
The pattern was different in cases. All six cases of end-stage
renal disease developed proteinuria, However, among cases of
stage 3–4 of CKD only 35% developed proteinuria – these
cases were most likely to have persistent microalbuminuria
(47%) or regress to normo-albuminuria (18%) despite
significant loss of renal function. Overall, the distributions
of the categories of albumin excretion rate change during the
12 years of follow up between controls and cases were highly
statistically significant (Po0.001). The data presented in
Table 2, however, did not address the issue of timing of the
development of proteinuria relative to the development of
advanced CKD in half of the cases (12 out of 23) that
developed both.
To further explore this question, we plotted the sequence
of urinary albumin excretion and GFRMDRD for representa-
tive examples from the six cases with end-stage renal disease
Table 2 | Estimated glomerular filtration rate and urinary albumin excretion at baseline and in the final 2-year evaluation
intervala
Controls (N=56) Cases (N=23)
Characteristic
GFR460ml/min per 1.73m2
‘CKD stages 1–2’ (N=56)
GFRp60ml/min per 1.73m2
‘CKD stages 3–4’ (N=17)
ESRD ‘CKD
stage 5’ (N=6) Pb
GFRMDRD (ml/min/1.73m
2)
Mean (min, max)
Baseline 107 (60, 164) 98 (73, 156) 101 (69, 134) 0.77
Final intervala 84 (61, 126) 50 (22, 59) 27 (4, 58) —
Urinary albumin excretion rate (in mg/min)
Median (interquartile range)
Baseline 49 (34, 68) 40 (34, 45) 46 (33, 69) 0.33
Final intervala 35 (16, 71) 52 (18, 241) 1285 (856, 2805) 0.06
Albumin excretion changes during 12 years of follow up
Remission to normo-albuminuria 28 (50%) 3 (18%) 0 (0%)
Persistent microalbuminuria 19 (34%) 8 (47%) 0 (0%) 0.001c
Progression to proteinuria 9 (16%) 6 (35%) 6 (100%)
Total 56 (100%) 17 (100%) 6 (100%)
Treatment with reno-protective drugs during the final interval a
ACE-inhibitor and ARBd 41 (73%) 11 (65%) 5 (83%) 0.45
CKD, chronic kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtration rate.
aThe final interval represents the 2-year interval at the end of observation for controls and cases with CKD stage 3–4, but the preceding interval for cases with CKD stage 5.
bComparison of cases and controls. As GFRMDRD in the final interval was involved in defining cases and controls, this variable was not tested. P-values for comparison of
proportions of cases in each albumin excretion rate class were calculated according to the w2-statistic using the contingency table method.
cIn the 2 3 table of case–control status versus course of urinary albumin excretion, w2 = 13.7, P = 0.001.
dAngiotensin receptor blocker (ARB) use was uncommon and present in five subjects, all of whom received valsartan. All exposure to valsartan was beyond 8 years after
microalbuminuria onset and was used in combination with angiotensin-converting enzyme (ACE) inhibitors in three of the five patients.
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(Figure 1). Five of the six cases, despite having GFRMDRD
near the normal range at the beginning of follow-up,
appeared to have loss of renal function at the time when
microalbuminuria was progressing to proteinuria (the two
processes were developing concurrently). Two such examples
are shown in panels (a) and (b). During the course of
microalbuminuria for these examples, GFRMDRD levels
clearly began to decline even before exposure to proteinuria.
In only one of the six cases could the timing of initiation of
decline not be determined relative to the onset of proteinuria
owing to infrequent GFRMDRD measures (panel c). Similar
examples from the 17 cases that developed stage 3–4 CKD are
shown in Figure 2. It is important to emphasize that in the
majority of these patients the development of advanced CKD
occurred in the absence of proteinuria.
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Figure 1 | Serial estimates of GFRMDRD (m) in ml/min per
1.73m2 and of urinary albumin excretion rate (*) in lg/min for
three representative cases of end-stage renal disease. (a)
Describes the clinical course of an individual who was followed for
approximately 4 years before the onset of microalbuminuria. After
8.8 years from the onset of microalbuminuria, end-stage renal
disease occurred (indicated by ‘E’). Although the end-stage renal
disease was preceded by proteinuria, the fifth estimate of
GFRMDRD indicates that renal function had already begun to
decline soon after the onset of microalbuminuria. The sixth
estimate of GFRMDRD was below 60ml/min per 1.73m
2 despite
short duration of exposure to proteinuria. (b) Describes a patient
who had decline in GFRMDRD to a level near 60ml/min per 1.73m
2
during the course of microalbuminuria. (c) Describes another case
of end stage renal disease preceded by proteinuria. However,
after only very short exposure to proteinuria the GFRMDRD had
declined to a level below 60ml/min per 1.73m2. Evidence that
decline in GFRMDRD had begun soon after the onset of
microalbuminuria was evident for five of the six cases of end-
stage renal disease (as in a and b). The arrows indicate the time of
initiation of angiotensin-converting enzyme inhibitor agents.
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Figure 2 | Serial estimates of GFRMDRD (m) in ml/min per
1.73m2 and of urinary albumin excretion rate (*) in lg/min for
three representative cases of stage 3–4 chronic kidney
disease. (a) Shows the clinical course of GFRMDRD for a stage 4
chronic kidney disease patient who developed proteinuria.
(b) Describes the course for a subject who developed stage 3
chronic kidney disease, but who had stable levels of urinary
albumin excretion rate in the microalbuminuria range without
developing proteinuria. (c) Describes the course of a subject with
stage 3 chronic kidney disease despite remission of urinary
albumin excretion to normoalbuminuria levels. In all of these
three examples, the initiation of renal function decline clearly
occurred during microalbuminuria-range albumin excretion. The
arrows indicate the time of initiation of angiotensin-converting
enzyme inhibitor agents.
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Relationship between angiotensin-converting enzyme
inhibitor use and advanced CKD
By the end of follow up, the use of angiotensin converting
enzyme inhibitor agents was common in both cases and
controls (Table 2). Of the 12 cases who developed
proteinuria, these agents were initiated before the onset of
proteinuria in 10 (83%) cases. Significant differences could
not be detected between cases and controls in the proportion
receiving angiotensin converting enzyme inhibitor agents, the
years of exposure, the proportion of observation time
exposed, or in the time of delay between the diagnosis of
microalbuminuria and initiation of therapy. Use of angio-
tensin receptor blocking agents was rare, and is described in
the legend to Table 2.
DISCUSSION
In a cohort of 79 subjects with type 1 diabetes, normal renal
function, and the documented new-onset of microalbumi-
nuria, the12-year risk of advanced CKD corresponding to
stage 3–5 was high (23 cases, 29%). Higher glycosylated
hemoglobin A1c and the development of proteinuria were
strongly associated with the risk of advanced-stage kidney
disease. However, nearly half of the cases never developed
proteinuria and, in those cases that did, the vast majority
began to lose renal function years before the development of
proteinuria independent of such factors as the use of
angiotensin converting enzyme inhibitor agents. Our study
showed uncoupling of risk of advanced CKD and progression
to proteinuria in patients with Type 1 diabetes and new-onset
microalbuminuria.
Presence of uncoupling of declining renal function and
progression of urinary albumin excretion in type 1 diabetes
was reported previously.15 Some authors observed declining
renal function in the absence of proteinuria in small
proportion of women with type 1 diabetes.15–17 However,
the uncoupling of risk of advanced CKD and progression to
proteinuria had not been examined systematically in
subjects with new-onset of microalbuminuria and type 1
diabetes. The traditional view is that advanced-CKD is
secondary to exposure to proteinuria.18–23 Although pre-
viously suspected,24–28a recent report from our research
group confirmed the existence of early renal function decline
in patients with microalbuminuria, quantified its risk, and
further proposed a method for its accurate estimation.12 The
systematic study, conducted in a large cohort of patients that
included both incident and prevalent microalbuminuria
cases, estimated serial GFRCYSTATIN C to determine trends
in renal function during microalbuminuria. Serum cystatin
C, unlike creatinine-based estimates, is a valid assay for renal
function prediction when it is in the normal or elevated
range.29–32 By calculating the linear slope of GFRCYSTATIN C,
our study demonstrated that the process of renal function
decline begins during the microalbuminuria stage in a third
of subjects, and that renal function may be elevated above
normal when the process starts.12 The present study builds
upon this notion by measuring the long-term risk of stage
3–5 CKD, a more clinically-relevant late-stage renal outcome,
specifically in those with the documented new-onset of
microalbuminuria. Our findings of uncoupling of the
development of advanced CKD from the exposure to
proteinuria have fundamental implications for the traditional
model of diabetic nephropathy that have previously placed
the time of initiation of renal function decline at the stage of
clinical proteinuria.4 A new model for diabetic nephropathy
emerges. The onset of microalbuminuria heralds, in a subset
of approximately one-third of individuals, a process of
progressive early renal function decline leading to advanced
CKD and ESRD that occurs irrespective or in parallel of the
progression of microalbuminuria to proteinuria. Microalbu-
minuria and early renal function decline may, thus, represent
two phenotypes that have separate underlying etiological
processes. This finding in part reconciles the results of recent
clinical trials that demonstrated a failure of therapies
designed to attenuate urinary albumin excretion on reducing
clinically meaningful renal function and renal morphology
endpoints.33–35
Similar to the findings observed in earlier studies,15–17 we
found an excess of advanced CKD in women as compared
with men. The magnitude of this excess in our study, however,
is uncertain. In the course of the study, 9 women and 21 men
were lost to follow-up from the new-onset microalbuminuria
cohort (see methods). In the group of men during the limited
follow up, we observed two cases of advanced CKD and
two deaths due to coronary artery disease. It is possible that
a few more such cases occurred in men, but they were not
ascertained. It should be recognized that this limitation does
not affect the validity of the conclusion of our study about
the uncoupling of risk of advanced CKD from the risk of
progression to proteinuria. Our study has some other
limitations. We used estimates of GFRMDRD rather than
direct measurement – a measure more accurate for GFR in
the normal or elevated ranges, such as cystatin C, might
reveal that the initiation of renal function decline occurs even
earlier in the course of microalbuminuria than was observed
in this analysis. In preliminary analysis using the limited
number of measurements of cystatin C available, we observed
higher GFRCYSTATIN values and steeper slopes of renal
function decline in some of the cases shown in Figures 1
and 2. Long-term systematic follow-up with cystatin C
measurements is the focus of a more recently accrued cohort
(the 2nd Joslin Kidney Study). Owing to limited power for
predictor variables, we cannot conclude a lack of a protective
association of renin–angiotensin system inhibitor agents
against advanced-stage kidney disease.5,9,36 That renal
function was commonly seen to decline regardless of such
anti-proteinuric therapy, though, does not diminish the
important implications of this work in further refining the
natural history of microalbuminuria and early renal function
decline.35
The emergence of this new model has fundamental
implications for research on the pathological mechanisms
and on potential biomarkers of diabetic nephropathy.
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Although the presence of microalbuminuria infers a 10-year
risk of progression to proteinuria in the range of 15–25%7–11 –
though the 12-year risk of advanced-stage kidney disease
approximates one-third—the degree or course of urinary
albumin excretion is not a sufficiently robust surrogate
marker for the development of CKD in type 1 diabetes. First,
microalbuminuria is a dynamic process—when it develops, it
can remain static, advance toward proteinuria, but most
frequently it regresses toward normal levels of albumin
excretion.7,8 Second, although the course of microalbumi-
nuria is generally correlated with the risk of renal function
decline,12 the predictive value is insufficient; decline occurs
frequently without the presence of overt proteinuria. This
new model of diabetic nephropathy demands that emphasis
be placed on research into better biomarkers that could
identify those at risk of advanced-stage kidney disease 5 to 10
years before its development.37 Such biomarkers could
enhance the utility of the conventional markers (micro-
albuminuria, serum creatinine) or replace them.
PATIENTS AND METHODS
Study participants
Patients with normo-albuminuria who developed micro-
albuminuria in the first 4 years of follow-up in the 1st Joslin
Kidney Study (in the previous publications it was referred to
as Joslin Kidney Study)7,13,38,39 were eligible for the current
project. The protocol and consent procedures were approved
by the Committee on Human Studies of the Joslin Diabetes
Center.
Urine samples from every second patient with type 1
diabetes who was 15–44 years of age and seen at the Joslin
Clinic between January 1991 and April 1992 were examined
(1602 patients). During the first 2 years, repeat urine samples
were examined to establish the albumin excretion status.
Members of the cohort with microalbuminuria at baseline
(n¼ 312) and proteinuria or end-stage renal disease at
baseline (n¼ 347) were excluded from the current analysis.
Within 4 years of initial evaluation, new-onset microalbu-
minuria developed in 109 out of 1080 patients with normo-
albuminuria at baseline and these patients with microalbu-
minuria were the focus of this report. They were examined
biennially, and additional urinary albumin excretion and
creatinine measurements were obtained from clinical visits.
We selected all individuals with at least five (on average 13)
creatinine measures spanning a minimum of 10 years after
the onset of microalbuminuria. In all 79 of the 109 patients
(72%) were available for analysis according to these criteria.
Among 30 patients (9 women and 21 men) who were
excluded from this study, 7 did not have any follow-up visit
except for the examination at enrollment. The remaining 23
patients were lost from the observation between the second
and tenth year of follow up (median 5 years). In these
individuals mean GFRMDRD at baseline was 102±25ml/min
per 1.73m2, very similar to those included in analysis. In this
group of 23 patients, during the limited follow up, 17 subjects
regressed to normo-albuminuria of which one reached
advanced CKD as of the last examination; 5 subjects
remained microalbuminuric of which none reached advanced
CKD; 1 subject progressed to proteinuria and this individual
developed advanced CKD, but before proteinuria occurred.
None of the 30 excluded individuals developed ESRD
according to registration in the United States Renal Data
System registry as of the end of 2005. As of the end of 2005,
according to the National Death Index, two subjects died
(both men, due to coronary artery disease). One of these
deaths occurred 8 years after the onset of microalbuminuria
in a patient who had regression from microalbuminuria to
normo-albuminuria. The second death occurred 9 years
after the onset of microalbuminuria in a patient who had
persistent microalbuminuria.
Assessment of urinary albumin excretion and exposure
variables
The albumin excretion rate (in mg/min) was estimated from
the albumin:creatinine ratio in random urine samples.7,38,39
Individual values for the albumin:creatinine ratio (measured
in mg/g) were transformed to a (base-10) logarithmic scale
for analysis and converted to albumin excretion rates (in mg/
min) by the formula log(AER)¼ 0.44 þ (0.85)log(ACR) –
(0.13)sex, where AER is the albumin excretion rate, ACR is
the albumin:creatinine ratio, and sex is assigned a value
of 1 for female patients and 0 for male patients.38,39 This
conversion formula was derived from an independent
sample of patients with type 1 diabetes who underwent
simultaneous determinations of the albumin:creatinine
ratio and the albumin excretion rate based on a 3 h
daytime collection (Pearson’s correlation coefficient, 0.97).
Follow-up observation was organized into 2-year intervals,
and patients were assigned an albumin excretion status for
each interval according to the geometric mean of their
determinations in that interval (on average 3): normo-
albuminuria was defined as an excretion rate less
than 30 mg/min; microalbuminuria 30–299 mg/min; and
proteinuria 300 mg/min or greater.
Estimation of glomerular filtration rate and definition of
advanced-CKD cases
The ‘four-variable’ estimating equation derived from the
Modification of Diet in Renal Disease Study Group was
applied to estimate glomerular filtration rate in ml/min
per 1.73m2, termed GFRMDRD, using the serum creatinine
level (in mg/dl), age, gender, and ethnicity.40,41 Serum
creatinine was measured throughout the study by a modi-
fied picrate method of Jaffe’s on a Ciba Corning Express
Plus Chemistry Analyzer. Although well validated in CKD,
the equation underestimates GFR in those with levels
above 60ml/min per 1.73m2.41–43 As such, we defined
advanced-stage kidney disease cases as those who attained a
level below this threshold (stage 3 CKD) or below 30ml/min
per 1.73m2 (stage 4 CKD). Stage 5 CKD (end-stage renal
disease) was designated if participants required dialysis or
renal transplantation in their clinical care. Subjects who
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maintained GFRMDRD levels X90ml/min per 1.73m
2 (stage
1 CKD) or 60 to 89ml/min per 1.73m2 (stage 2 CKD) were
classified as controls.41 Clinical records were reviewed by a
nephrologist (B.R.) to determine the cause of renal disease.
For descriptive purposes, we also estimated GFR during
the first years of microalbuminuria from the measurement of
serum cystatin C (GFRCYSTATIN C) on a BN Prospec System
nephelometer (Dade Behring Incorporated, Newark, DE,
USA) using a validated conversion formula defined by
GFRCYSTATIN C in ml/min per 1.73m
2¼ (86.7/cystatin C
concentration) 4.2.29,44
Analysis
Analyses were carried out in SAS (version 9.1 for Windows).
Differences between cases and controls at baseline were
assessed using w2 tests for categorical variables or t-tests for
continuous variables. Significance was based on an a-level of
0.05. Individual determinations of the albumin excretion rate
were transformed to the logarithmic scale (base 10) for
analysis. The risk of advanced CKD was estimated by
cumulative incidence.
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